|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Avenue Therapeutics, Inc. (ATXI) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
16,750,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Avenue Therapeutics is a pharmaceutical company that develop and commercialize its product principally for use in the acute/intensive care hospital setting. Co.'s product candidate is intravenous (IV) Tramadol, for the treatment of post-operative acute pain. Tramadol, a synthetic dual-acting opioid, is a centrally acting analgesic with weak opioid agonist properties. It also works via the inhibition of serotonin and noradrenaline re-uptake and blocking nociceptive impulses at the spinal level. Co. has completed a pharmacokinetic study for IV Tramadol in healthy volunteers. Co. also has initiated a Phase 3 development program of IV Tramadol for the management of post-operative pain.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
767,085 |
767,085 |
| Total Buy Value |
$0 |
$0 |
$552,301 |
$552,301 |
| Total People Bought |
0 |
0 |
2 |
2 |
| Total Buy Transactions |
0 |
0 |
2 |
2 |
| Total Shares Sold |
0 |
617,000 |
617,000 |
1,005,888 |
| Total Sell Value |
$0 |
$86,560 |
$86,560 |
$3,086,442 |
| Total People Sold |
0 |
1 |
1 |
2 |
| Total Sell Transactions |
0 |
2 |
2 |
3 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Reines Scott |
Interim Chief Medical Officer |
• – – |
2018-08-07 |
4 |
GA |
$0.00 |
$0 |
D/D |
10,000 |
45,000 |
|
- |
|
| Lu Lucy |
President, CEO |
• • – |
2018-08-07 |
4 |
GA |
$0.00 |
$0 |
D/D |
250,000 |
807,333 |
|
- |
|
| Paley Jeffrey |
Director |
– • – |
2018-08-07 |
4 |
GA |
$0.00 |
$0 |
D/D |
14,663 |
64,663 |
|
- |
|
| Herskowitz Neil |
Director |
– • – |
2018-08-07 |
4 |
GA |
$0.00 |
$0 |
D/D |
14,663 |
67,163 |
|
- |
|
| Weiss Michael S |
Director |
– • – |
2018-08-07 |
4 |
GA |
$0.00 |
$0 |
D/D |
14,663 |
24,663 |
|
- |
|
| Rosenwald Lindsay A Md |
Director |
– • – |
2018-08-07 |
4 |
GA |
$0.00 |
$0 |
D/D |
14,663 |
84,663 |
|
- |
|
| Samad Akhtar |
Director |
– • – |
2018-08-07 |
4 |
GA |
$0.00 |
$0 |
D/D |
14,663 |
64,663 |
|
- |
|
| Vazzano Joseph Walter |
VP Finance & Corp. Controller |
• – – |
2018-06-28 |
4 |
A |
$3.66 |
$4,945 |
D/D |
1,351 |
31,351 |
|
- |
|
| Lu Lucy |
President, CEO |
• • – |
2018-06-14 |
4 |
A |
$4.00 |
$20,000 |
D/D |
5,000 |
557,333 |
|
- |
|
| Rosenwald Lindsay A Md |
Director |
– • – |
2018-06-08 |
4/A |
B |
$4.34 |
$22,727 |
D/D |
5,234 |
70,000 |
2.39 |
- |
|
| Rosenwald Lindsay A Md |
Director |
– • – |
2018-06-08 |
4 |
B |
$4.34 |
$22,716 |
D/D |
5,234 |
25,234 |
2.39 |
- |
|
| Rosenwald Lindsay A Md |
Director |
– • – |
2018-06-07 |
4/A |
B |
$4.32 |
$63,969 |
D/D |
14,800 |
64,766 |
2.39 |
- |
|
| Rosenwald Lindsay A Md |
Director |
– • – |
2018-06-06 |
4/A |
B |
$4.35 |
$39,576 |
D/D |
9,100 |
49,966 |
2.39 |
- |
|
| Rosenwald Lindsay A Md |
Director |
– • – |
2018-06-05 |
4/A |
B |
$4.28 |
$35,949 |
D/D |
8,400 |
40,866 |
2.39 |
- |
|
| Rosenwald Lindsay A Md |
Director |
– • – |
2018-06-04 |
4/A |
B |
$4.19 |
$15,921 |
D/D |
3,800 |
32,466 |
2.39 |
- |
|
| Rosenwald Lindsay A Md |
Director |
– • – |
2018-06-01 |
4/A |
B |
$4.15 |
$36,003 |
D/D |
8,666 |
28,666 |
2.39 |
- |
|
| Herskowitz Neil |
Director |
– • – |
2018-04-25 |
4 |
B |
$3.80 |
$3,800 |
D/D |
1,000 |
52,500 |
2.31 |
- |
|
| Herskowitz Neil |
Director |
– • – |
2017-10-17 |
4 |
B |
$5.01 |
$5,010 |
D/D |
1,000 |
51,500 |
2.39 |
- |
|
| Herskowitz Neil |
Director |
– • – |
2017-10-09 |
4 |
B |
$5.24 |
$2,620 |
D/D |
500 |
50,500 |
2.31 |
- |
|
| Rosenwald Lindsay A Md |
Director |
– • – |
2017-10-09 |
4 |
B |
$5.40 |
$7,290 |
D/D |
1,350 |
20,000 |
2.39 |
- |
|
| Rosenwald Lindsay A Md |
Director |
– • – |
2017-10-06 |
4 |
B |
$5.63 |
$16,327 |
D/D |
2,900 |
18,650 |
2.39 |
- |
|
| Rosenwald Lindsay A Md |
Director |
– • – |
2017-10-05 |
4 |
B |
$5.60 |
$19,880 |
D/D |
3,550 |
15,750 |
2.39 |
- |
|
| Rosenwald Lindsay A Md |
Director |
– • – |
2017-10-04 |
4 |
B |
$5.60 |
$12,320 |
D/D |
2,200 |
12,200 |
2.39 |
- |
|
| Lu Lucy |
President, CEO |
• • – |
2017-09-28 |
4 |
A |
$5.20 |
$20,800 |
D/D |
4,000 |
552,333 |
|
- |
|
| Vazzano Joseph Walter |
VP Finance & Corp. ControllerO |
• – – |
2017-08-08 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
30,000 |
|
- |
|
85 Records found
|
|
Page 3 of 4 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
